We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+23.99%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$411M
AUM Growth
+$56.5M
Cap. Flow
+$30.1M
Cap. Flow %
7.32%
Top 10 Hldgs %
65.77%
Holding
29
New
3
Increased
13
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$9.15M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$7.4M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$6.68M
4
VYGR icon
Voyager Therapeutics
VYGR
+$5.49M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.04M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$19.1M
2
TSRO
TESARO, Inc.
TSRO
+$4.97M
3
OVID icon
Ovid Therapeutics
OVID
+$436K

Sector Composition

Rank Sector Weight
1 Healthcare 93.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVID icon
26
Ovid Therapeutics
OVID
$435M
$1.58M 0.38%
160,000
-47,500
-23% -$436K
AGIO icon
27
CALL
Agios Pharmaceuticals
AGIO
$1.82B
$1.43M 0.35%
+25,000
New +$1.57M
TSRO
28
DELISTED
TESARO, Inc.
TSRO
– –
-38,500
Closed -$4.97M
KITE
29
DELISTED
Kite Pharma, Inc.
KITE
– –
-106,000
Closed -$19.1M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Casdin Capital held 29 positions worth $411M, up 16% from $354M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Casdin Capital deployed $30.1M of net new capital in Q4 2017, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was Gilead Sciences: 30,000 shares worth $2.15M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Ovid Therapeutics, an estimated $436K trimmed.

  • Casdin Capital's largest Q4 2017 buy was Gilead Sciences: 30,000 shares worth $2.15M.
  • Casdin Capital added most to Fate Therapeutics in Q4 2017, an estimated $9.15M increase.
  • Casdin Capital's biggest Q4 2017 reduction was Ovid Therapeutics, cutting an estimated $436K.
  • Casdin Capital fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $19.1M.
  • Casdin Capital's ten largest holdings make up 66% of its $411M portfolio in Q4 2017.
  • Casdin Capital opened 3 new positions and closed 2 in Q4 2017.
  • Casdin Capital's portfolio value rose 16% quarter-over-quarter to $411M.

Based on Casdin Capital's 13F filing for Q4 2017, filed 14 Feb 2018.